ASTELLAS AND MEDIVATION SUBMIT SUPPLEMENTAL NEW DRUG APPLICATION FOR XTANDI (ENZALUTAMIDE) FOR CHEMOTHERAPY-NAÏVE ADVANCED PROSTATE CANCER

[at noodls] – TOKYO, JAPAN and SAN FRANCISCO, CA – March 18, 2014 – Astellas Pharma Inc. (TSE: 4503) and Medivation Inc. (NASDAQ: MDVN) today announced the submission of a supplemental New Drug Application (sNDA) to … more

View todays social media effects on MDVN

View the latest stocks trending across Twitter. Click to view dashboard

See who Medivation is hiring next, click here to view